

Investigating COVID-19 infection in patients with acute myeloid leukaemia (AML) undergoing chemotherapy

Submission date 20/05/2021	Recruitment status No longer recruiting	☐ Prospectively registered ☐ Protocol
Registration date 28/11/2022	Overall study status Completed	☐ Statistical analysis plan ☒ Results
Last Edited 18/09/2025	Condition category Cancer	☐ Individual participant data

Plain English summary of protocol

Background and study aims

The pandemic of Coronavirus disease 2019 (COVID-19) is having major implications on healthcare globally with an estimated around 1-2% of patients dying from the disease. This risk increases with age and this is particularly important for patients with cancer where age is also a risk factor. It is possible a large proportion of the population could become infected with COVID-19. As the prevalence of COVID-19 in the UK is not known due to limited testing, it is not possible to accurately estimate what proportion of patients will have a history of, or will go on to develop, COVID-19. In patients over the age of 60, the hospitalisation rate is estimated to be around 16%, with a quarter requiring Intensive care support and a death rate of 2%.

Acute Myeloid Leukaemia (AML) is a type of cancer that starts in the bone marrow, where the blood cells that fight infections in the body are produced. AML affects predominantly the elderly with a peak of cases at over 70 years of age. There is some early evidence to suggest that patients with cancer are more likely to develop severe COVID-19 disease. Patients during the pandemic will continue to develop AML and it is not possible to delay starting treatment for this aggressive disease for the number of months it may take for the current pandemic to subside. AML is potentially curable with intensive chemotherapy and therefore the recommendation has been not to delay starting treatment. However, there is no data to inform practice in patients with AML who develop COVID-19. A recommendation is to test all patients with a new diagnosis of AML for COVID-19. At present, it is not clear whether patients should be managed with intensive, inpatient standard chemotherapy schedules that will leave patients more immunosuppressed but with better cancer survival rates. This will also require a longer bed occupancy which is a critical issue during this coronavirus pandemic. Furthermore, early evidence suggests that SARS-CoV2 transmission between cancer patients is largely dependent on hospital-acquired transmission. Therefore, it will be important to understand the survival of patients treated with both intensive and non-intensive chemotherapy schedules during this era.

A further complication is that patients with AML are well established to be vulnerable to severe invasive bacterial and fungal infections; infection remains a major cause of morbidity and mortality in AML. It is important to rapidly define the impact of COVID-19 infection on the

mortality rate and how best to manage COVID-19 alongside these expected bacteria/fungal invasive infections.

This study aims to collect data on the outcomes of patients with AML who develop COVID-19 infection, and the rates and severity of all infections in patients with AML undergoing intensive chemotherapy, including in those who have recovered from prior COVID-19 infection or who develop COVID-19. This information will be essential to design new studies and update current recommendations.

Who can participate?

Adult patients with acute myeloid leukaemia (AML) or Myelodysplastic Syndrome With Excess Blasts (MDS-EB2) currently receiving, or due to receive, treatment.

What does the study involve?

Demographic data and medical history will be collected for all participants at the start of the study. This will include pre-existing conditions such as diabetes and any history of COVID-19 infection. All patients will also be tested at baseline for COVID-19 and this data will be collected. Data will also be collected on the patient's treatment plan for their AML.

For the 6 months after joining the study, data will be collected on each participant on a weekly basis. Information can be obtained from the hospital notes so patients do not need to attend the clinic. This will include data on any COVID-19 diagnosis, symptoms and outcome, and data on any hospital admissions. Type of infection, diagnostic assessments, antibiotic/antifungal prophylaxis, and how these are treated will be reported. At monthly intervals, there will be an additional form to provide data on any bone marrow assessments the patient has had for their AML and also their survival status. Patients will be followed up for survival until the end of the study. Then, for the following 6 months, patients will be followed up 3 monthly for evidence of COVID-19 infection, AML treatment, and disease response and survival.

If the patient has consented to participate in the sampling sub-study, blood, stool, saliva, and sputum samples would be requested upon entry into the sub-study, and every month for 6 months. Additional samples are requested if the patient is hospitalised with an infection (upon admission to hospital, and 4 weeks later). If a patient doesn't wish to provide a certain sample, or if it is inappropriate to ask for a sample at a certain timepoint, the time point should be missed.

What are the possible benefits and risks of participating?

Participants will be fully informed of the risks and benefits of taking part in the study, along with the burdens involved. As the main study is a non-interventional study that will only collect data and there are no assessments additional to standard of care, the risks are minimal. Any additional risks and burdens through participating in the optional sampling sub-study have been described in the PIS. It is hoped the information gained from this study may help to improve the care of AML patients in the future. The sample collection in the sub-study will not result in any additional visits for patients and blood samples would be taken at the same time as any routine samples.

Where is the study run from?

University of Birmingham (UK)

When is the study starting and how long is it expected to run for?

From January 2020 to March 2023

Who is funding the study?
Cure Leukaemia (UK) and the National Institute for Health Research (UK)

Who is the main contact?
pace@trials.bham.ac.uk

Contact information

Type(s)

Principal investigator

Contact name

Prof Simon Standworth

ORCID ID

<https://orcid.org/0000-0002-7414-4950>

Contact details

University of Oxford
John Radcliffe Hospital
Headley Way
Headington
Oxford
United Kingdom
OX3 9DU
+44 (0)1865 741166
simon.stanworth@nhsbt.nhs.uk

Type(s)

Public

Contact name

Ms Tina Tang

Contact details

Cancer Research UK Clinical Trials Unit (CRCTU)
Centre of Clinical Haematology
University of Birmingham
Edgbaston
Birmingham
United Kingdom
B15 2TH
+44 (0)121 371 7863
pace@trials.bham.ac.uk

Additional identifiers

Integrated Research Application System (IRAS)
282870

Study information

Scientific Title

The impact of COVID-19 on patients with AML undergoing chemotherapy: an epidemiological study

Acronym

PACE

Study objectives

To understand the incidence of COVID-19 infection during treatment of Acute Myeloid Leukaemia (AML)

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 01/05/2020, North of Scotland Research Ethics Committee (Currently being held remotely via Zoom video-conference; +44 (0)1224558458; gram.nosres@nhs.scot), ref: 20/NS/0059

Primary study design

Observational

Study design

Observational cohort study

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Acute myeloid leukaemia, COVID-19 (SARS-CoV-2 infection)

Interventions

Patients with AML may participate in this study if they have a newly diagnosed disease, if they are currently receiving treatment for AML or if their AML has returned (relapsed) and they are due to have treatment with chemotherapy. It is thought approximately 50% of patients will be receiving intensive chemotherapy and around 50% will be receiving non-intensive chemotherapy.

Demographic data, medical history, and ECOG performance status will be collected for all patients at baseline. This will include pre-existing conditions such as diabetes and any history of COVID-19 infection. All patients will also be tested at baseline for COVID-19 as per the standard of care and this data will be collected. Data will also be collected on the patient's treatment plan for their AML.

For 6 months following study entry, data will be collected on each patient for the study on a weekly basis. Information can be obtained from the hospital notes so patients do not need to

attend the clinic. This will include data on any COVID-19 diagnosis, symptoms and outcome, and data on any hospital admissions. Type of infection, diagnostic assessments, antibiotic/antifungal prophylaxis, and treatment will be reported.

At monthly intervals, there will be an additional form to provide data on any bone marrow assessments the patient has had for their AML and also their survival status. Patients will be followed up for survival until the end of the study.

For the following 6 months, patients will be followed up 3 monthly for evidence of COVID-19 infection, AML treatment, and disease response and survival.

If the patient has consented to the sampling sub-study, blood, stool, saliva, and sputum samples would be requested upon entry into the sub-study, and every month for 6 months. Additional samples are requested if the patient is hospitalised with an infection (upon admission to hospital, and 4 weeks later). If a patient doesn't wish to provide a certain sample, or if it is inappropriate to ask for a sample at a certain timepoint, the time point should be missed.

Intervention Type

Other

Primary outcome(s)

Incidence of COVID-19 infection developing during AML treatment measured using SAR-CoV-2 PCR test and from hospital records from baseline until 4 weeks subsequent to the last cycle of treatment

Key secondary outcome(s)

Prospective study outcomes:

1. Symptoms and severity of COVID-19 infection in patients with AML measured using patient notes (of patient hospitalisation, requiring oxygen, and ITU admission), completing weekly follow-up forms (was oxygen saturation <92% and does the patient have sustained increased respiratory rate?) between baseline and 24 months
2. Survival at Day 30 and 60, with or without a diagnosis of COVID-19 at presentation, or at any stage, measured using CRFs, monthly follow up forms, treatment form, and baseline form at 30 and 60 days
3. Overall survival measured using patient notes at first diagnosis until death
4. The number of episodes of bacteraemia/presumed fungal infection in AML patients measured using patient notes, all documented in the admission/infection form (reviewing if blood culture was performed, serum fungal test performed, and CT chest performed) between baseline and 24 months
5. The severity of episodes of bacteraemia/presumed fungal infection in AML patients measured using the length of the episode, days in ICU, duration of hypotension, and CTCAE V4 grading between baseline and 24 months
6. Use of anti-viral agents as prophylaxis and therapy in this high-risk population (including convalescent plasma) measured using the number of occasions anti-viral agents were used (including convalescent plasma), and the number and proportion of patients who have received them, recorded in hospital records between baseline and 24 months
7. Prevalence of prior COVID-19 infection at the time of AML presentation measured using the presence of positive IgG (although recognising that some patients with AML may have significant hypogammaglobulinaemia) at baseline

8. Development of COVID-19 antibodies (IgG and/or IgM) during AML treatment measured using the presence of positive IgG (although recognising that some patients with AML may have significant hypogammaglobulinaemia) at 24 months

Retrospective cohort outcomes:

1. Symptoms and severity of COVID-19 infection in patients with AML or MDS-EB2 using SAR-CoV-2 PCR test and from hospital records at the time COVID-19 infection is identified

Vaccine cohort outcomes:

1. Immune response to COVID-19 vaccination at 4 weeks following vaccination (first, second, third and fourth vaccine where possible) in patients with AML or MDS-EB2 measured using blood samples taken (antibody and t-cell response data) at 4 weeks after vaccination

2. Immune response to COVID-19 vaccination at 6 months post second vaccine (or pre-third dose) in patients with AML or MDS-EB2 measured using blood samples taken (antibody and t-cell response data) at 6 months after the second vaccination

3. Influence of treatment regimen on the immune response to COVID-19 vaccination in patients with AML or MDS-EB2 measured using vaccine treatment and vaccine form an antibody and t-cell response data from blood samples taken at all timepoints (4 weeks post 1st, 2nd, 3rd, and 4th vaccines and 6 months post 2nd vaccine)

4. Influence of disease status on the immune response to COVID-19 vaccination in patients with AML or MDS-EB2 measured using baseline form, and antibody and t-cell response data from blood samples taken at all timepoints (4 weeks post 1st, 2nd, 3rd, and 4th vaccines and 6 months post 2nd vaccine)

Completion date

31/03/2023

Eligibility

Key inclusion criteria

1. Acute myeloid leukaemia (AML) including known AML presenting with relapse or Myelodysplastic Syndrome With Excess Blasts (MDS-EB2)

2. Currently receiving (at any treatment stage), or planned for, intensive (i.e. curative intent) or non-intensive chemotherapy. Intensive treatment includes regimens including Daunorubicin /Cytarabine, Fludarabine/Cytarabine/Idarubicin, intermediate/high dose Cytarabine, CPX-351, Gemtuzumab Ozogamacin, Midostaurin. Non-intensive treatments include Azacitidine, low dose Cytarabine, and Venetoclax based regimens.

3. Written informed consent to participate

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Total final enrolment

321

Key exclusion criteria

1. Aged <16 years
2. Undergoing allogeneic stem cell transplant at trial entry
3. Supportive care only (including hydroxycarbamide alone)
4. Acute promyelocytic leukaemia (APML)

Date of first enrolment

13/05/2020

Date of final enrolment

30/06/2021

Locations**Countries of recruitment**

United Kingdom

England

Northern Ireland

Scotland

Wales

Study participating centre**Oxford University Hospitals NHS Foundation Trust**

John Radcliffe Hospital

Headley Way

Headington

Oxford

United Kingdom

OX3 9DU

Study participating centre**Guy's and St Thomas' NHS Foundation Trust**

St Thomas' Hospital

Westminster Bridge Road

London

United Kingdom

SE1 7EH

Study participating centre

Guy's and St Thomas' NHS Foundation Trust

St Thomas' Hospital
Westminster Bridge Road
London
United Kingdom
SE1 7EH

Study participating centre

Sheffield Teaching Hospitals NHS Foundation Trust

Northern General Hospital
Herries Road
Sheffield
United Kingdom
S5 7AU

Study participating centre

Belfast Health and Social Care Trust

Trust Headquarters
A Floor - Belfast City Hospital
Lisburn Road
Belfast
United Kingdom
BT9 7AB

Study participating centre

Cardiff and Vale NHS Trust

Cardigan House
University Hospital of Wales
Heath Park
Cardiff
United Kingdom
CF14 4XW

Study participating centre

University College London Hospitals NHS Foundation Trust

250 Euston Road
London
United Kingdom
NW1 2PG

Study participating centre

The Royal Wolverhampton NHS Trust

New Cross Hospital
Wolverhampton Road
Heath Town
Wolverhampton
United Kingdom
WV10 0QP

Study participating centre

James Paget University Hospitals NHS Foundation Trust

Lowestoft Road
Gorleston
Great Yarmouth
United Kingdom
NR31 6LA

Study participating centre

University Hospitals Coventry and Warwickshire NHS Trust

Walsgrave General Hospital
Clifford Bridge Road
Coventry
United Kingdom
CV2 2DX

Study participating centre

University Hospitals of North Midlands NHS Trust

Newcastle Road
Stoke-on-trent
United Kingdom
ST4 6QG

Study participating centre

Royal Berkshire NHS Foundation Trust

Royal Berkshire Hospital
London Road
Reading
United Kingdom
RG1 5AN

Study participating centre

University Hospitals Bristol and Weston NHS Foundation Trust

Trust Headquarters
Marlborough Street
Bristol
United Kingdom
BS1 3NU

Study participating centre

University Hospitals Birmingham NHS Foundation Trust

Queen Elizabeth Hospital
Mindelsohn Way
Edgbaston
Birmingham
United Kingdom
B15 2GW

Study participating centre

NHS Greater Glasgow and Clyde

J B Russell House
Gartnavel Royal Hospital
1055 Great Western Road Glasgow
Glasgow
United Kingdom
G12 0XH

Study participating centre

Nottingham University Hospitals NHS Trust

Trust Headquarters
Queens Medical Centre
Derby Road
Nottingham
United Kingdom
NG7 2UH

Study participating centre

The Christie NHS Foundation Trust

550 Wilmslow Road
Withington
Manchester
United Kingdom
M20 4BX

Study participating centre

Great Western Hospitals NHS Foundation Trust

Great Western Hospital
Marlborough Road
Swindon
United Kingdom
SN3 6BB

Study participating centre

Countess of Chester Hospital NHS Foundation Trust

Countess of Chester Health Park
Liverpool Road
Chester
United Kingdom
CH2 1UL

Study participating centre

Northampton General Hospital NHS Trust

Cliftonville
Northampton
United Kingdom
NN1 5BD

Study participating centre

Milton Keynes University Hospital NHS Foundation Trust

Standing Way
Eaglestone
Milton Keynes
United Kingdom
MK6 5LD

Study participating centre

NHS Grampian

Summerfield House
2 Eday Road
Aberdeen
United Kingdom
AB15 6RE

Study participating centre

The Newcastle upon Tyne Hospitals NHS Foundation Trust

Freeman Hospital
Freeman Road
High Heaton
Newcastle upon Tyne
United Kingdom
NE7 7DN

Study participating centre**Leeds Teaching Hospitals NHS Trust**

St. James's University Hospital
Beckett Street
Leeds
United Kingdom
LS9 7TF

Sponsor information

Organisation

University of Birmingham

ROR

<https://ror.org/03angcq70>

Funder(s)

Funder type

Charity

Funder Name

Cure Leukaemia

Funder Name

National Institute for Health Research (NIHR) (UK)

Alternative Name(s)

National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

Funding Body Type

Government organisation

Funding Body Subtype
National government

Location
United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan
The datasets generated and/or analysed during the current study will be published as a supplement to the results publication

IPD sharing plan summary
Published as a supplement to the results publication

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		12/06/2023	18/09/2025	Yes	No
Basic results		18/07/2024	30/07/2024	No	No
HRA research summary			28/06/2023	No	No
Participant information sheet	version 1.0		11/02/2022	No	Yes
Participant information sheet	version 7.0	07/12/2021	11/02/2022	No	Yes
Participant information sheet	version 3.0	07/12/2021	11/02/2022	No	Yes